How much revenue does HBM Holdings make?

HBM Holdings reported $157.98 million in revenue for fiscal year 2025, up 314.6% from $38.10 million in fiscal year 2024.

Where does HBM Holdings make most of its revenue?

Europe: 58% of revenue by region in fiscal year 2025, followed by Others (27%).

What companies are similar to HBM Holdings?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Akeso, Inc. (9926.HK), Shanghai Henlius Biotech, Inc. (2696.HK), Keymed Biosciences Inc. (2162.HK), CStone Pharmaceuticals (2616.HK).

HBM Holdings Limited (2142.HK) Stock

About HBM Holdings Limited

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is...

At a glance

HBM Holdings reported revenue of $157.98 million for fiscal year 2025, up 314.6% from fiscal year 2024, and net income of $91.33 million. Europe was its largest region in fiscal year 2025, with 58% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.